Some global biopharma companies present here include Johnson & Johnson, Alcon, Novartis, Pfizer, and Roche. Biotech is rapidly gaining traction in Europe. Simply put, Europe is one of the leading regions for life science industry in the world. This enables researchers and funders to tackle problems and research question they otherwise could not have solved on their own. Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019. “Because biotech is so risky most of the time, there are not so many willing to invest.”. © 2020 Questex LLC. As well as within biotech hubs, there are issues to tackle in European biotech investment as a whole. Jeito has been set up with a focus on women founders so that diversity can get a much-needed boost in biotech startups. This BioM hub also has two incubators solely dedicated to the biotechnology sector. One of the major reasons for the excellent reputation of this hub is its excellence in modern medical technologies and the latest innovations. Switzerland has had one of the best track records in Europe for developing a homegrown drug development industry, but it's done it all with private capital and virtually no public support. “That’s not the case anymore.”, Despite the improvements across Cambridge and Paris, biotech companies in both hubs have a hard time getting funding at the early stages. With the continued success of these life science hubs and a growing interest in the biopharma industry, more European nations are striving to emulate them. Jeito will also have a nonprofit arm for mentoring women founders. The European Technology Platform for Sustainable Chemistry was officially launched in 2004 as a European Commission supported initiative to revitalise and inspire European chemistry and industrial biotechnology research, development and innovation in a sustainable way. The investment options are now generally less risky and more scientifically grounded than in the past. For decades European countries have been among the most innovative on the planet when it comes to drug development. Do you want to join 10 000 subscribers who receive the hottest biotech news in their inbox every Friday (for free)? Biotechnology research is multidisciplinary and relies on the availability of various facilities and services. exclude terms. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. To help those trying to pick one of the many biotech hubs in Europe, I have compiled a list of where some of the most exciting biotech companies are based. Major pharma companies like GlaxoSmithKline, Roche, Sanofi-Aventis and Novartis, meanwhile, have nurtured top talent in their ranks, creating an intelligentsia of experienced managers and scientists skilled at recognizing the market value of new therapies. All of these project initiatives bear close observation in the U.S., where public support for biotech has been a prominent feature in a slate of key states. of the total investments in 2018, and biotechnology is no exception to this trend. This hub houses about 250 companies, out of which 118 are small and medium-sized enterprises (SME). Members of the European Federation of Pharmaceutical Industries and Associations are committing €1 billion in resources to match the €1 billion in cash coming from the European Commission. “I probably spend half of my time networking and trying to bring VCs together to fill rounds,” said Milner. “. ... It’s the first and the largest life science-oriented hub in Europe. Europe’s role in this industry continues to grow, and the region leads in many ways. By resolving core issues like gender diversity, communication, and continuity of funding in the biotech field, investors could overcome many limitations. The bioeconomy plays an important role in these initiatives and will be key to tackling, amongst others, the following challenges: The following JPIs are relevant to the biotechnology sector: Tackling the challenge of agriculture, food security and climate change, Working towards sustainable water systems, Joint Programming Initiative Connecting Climate Knowledge for Europe, Promoting a healthy diet for a healthy life, Working towards healthy and productive seas and oceans, Working on the challenge of neurodegenerative diseases, Working on the challenge of antimicrobial resistance. Just last month the IMI entered a new stage of development with a €156 million call for research proposals. Angel investors often don’t have the resources to invest in these larger rounds, and it can be hard to attract VC investors. Life science investors differ widely across biotech hubs in Europe. In the biotechnology space, the following ERA-NETs (or their follow-on programmes) are currently active: Promote the implementation of systems biology approaches in clinical research and medical practice, Towards sustainable food production and consumption, Strengthen research and innovation in materials science and engineering, Improve collaboration in science, technology and innovation between Latin America and Europe, improve collaboration in science, technology and innovation between Russia and Europe, Improve collaboration in science, technology and innovation between Japan and Europe, Develop a diverse but integrated food and non-food biomass production and transformation system, Improve research and innovation in personalised medicine, Coordinate and promote efforts for funding research on rare diseases by creating a research and innovation pipeline “from bench to bedside”.